DE60113286D1 - Oral aktive salze mit tyrosinkinaseaktivität - Google Patents

Oral aktive salze mit tyrosinkinaseaktivität

Info

Publication number
DE60113286D1
DE60113286D1 DE60113286T DE60113286T DE60113286D1 DE 60113286 D1 DE60113286 D1 DE 60113286D1 DE 60113286 T DE60113286 T DE 60113286T DE 60113286 T DE60113286 T DE 60113286T DE 60113286 D1 DE60113286 D1 DE 60113286D1
Authority
DE
Germany
Prior art keywords
tyrosine kinase
active salts
kinase activity
oral active
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60113286T
Other languages
English (en)
Other versions
DE60113286T2 (de
Inventor
E Fraley
B Karki
Yuntae Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60113286D1 publication Critical patent/DE60113286D1/de
Publication of DE60113286T2 publication Critical patent/DE60113286T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60113286T 2000-10-17 2001-10-17 Oral aktive salze mit tyrosinkinaseaktivität Expired - Fee Related DE60113286T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24104300P 2000-10-17 2000-10-17
US241043P 2000-10-17
PCT/US2001/032508 WO2002032861A2 (en) 2000-10-17 2001-10-17 Orally active salts with tyrosine kinase activity

Publications (2)

Publication Number Publication Date
DE60113286D1 true DE60113286D1 (de) 2005-10-13
DE60113286T2 DE60113286T2 (de) 2006-06-22

Family

ID=22909009

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60113286T Expired - Fee Related DE60113286T2 (de) 2000-10-17 2001-10-17 Oral aktive salze mit tyrosinkinaseaktivität

Country Status (9)

Country Link
US (2) US6960590B2 (de)
EP (1) EP1328519B1 (de)
JP (1) JP2004511541A (de)
AT (1) ATE303998T1 (de)
AU (2) AU2687702A (de)
CA (1) CA2424689A1 (de)
DE (1) DE60113286T2 (de)
ES (1) ES2247187T3 (de)
WO (1) WO2002032861A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
KR100728797B1 (ko) 2000-09-11 2007-06-19 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
EP1328519B1 (de) * 2000-10-17 2005-09-07 Merck & Co., Inc. Oral aktive salze mit tyrosinkinaseaktivität
WO2003020276A1 (en) * 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1496982A4 (de) * 2002-04-16 2006-07-19 Merck & Co Inc Feste formen von salzen mit tyrosinkinase-wirkung
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
US7470709B2 (en) 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
CA2542007C (en) * 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
EP1633694A4 (de) * 2003-06-05 2007-03-14 Merck & Co Inc Substituierte indole und verfahren zur herstellung substituierter indole
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
ATE530533T1 (de) 2005-05-17 2011-11-15 Novartis Ag Verfahren zur synthese heterocyclischer verbindungen
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006304897B2 (en) 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
WO2007124316A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
CN101472914B (zh) 2006-04-20 2015-05-20 詹森药业有限公司 C-fms激酶抑制剂
EP2405270B1 (de) 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2121681B1 (de) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Verbindungen und verfahren zur behandlung von krebs
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2702637A1 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2318406B1 (de) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren
WO2010114896A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
JP5734313B2 (ja) 2010-01-12 2015-06-17 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
IN2015DN00659A (de) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CN107001283B (zh) 2014-07-31 2021-05-25 国家健康与医学研究院 Flt3受体拮抗剂
EP3254698A1 (de) 2016-06-08 2017-12-13 Universite De Montpellier Flt3-rezeptor-inhibitoren bei niedriger dosierung zur behandlung von neuropathischem schmerz
CN109640991A (zh) 2016-07-29 2019-04-16 詹森药业有限公司 治疗前列腺癌的方法
US10305868B2 (en) * 2016-09-30 2019-05-28 Uchicago Argonne, Llc Stream splitting moving target defense
AU2017353925A1 (en) 2016-11-02 2018-09-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
CN111093640A (zh) 2017-05-17 2020-05-01 国家健康与医学研究院 用于改善阿片类药物疼痛治疗的flt3抑制剂
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5578609A (en) 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
US6162813A (en) 1996-05-20 2000-12-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU4718997A (en) 1996-11-27 1998-06-22 Pfizer Inc. Fused bicyclic pyrimidine derivatives
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
ATE286045T1 (de) 1999-10-19 2005-01-15 Merck & Co Inc Tyrosin kinaseinhibitoren
EP1328519B1 (de) * 2000-10-17 2005-09-07 Merck & Co., Inc. Oral aktive salze mit tyrosinkinaseaktivität

Also Published As

Publication number Publication date
WO2002032861A2 (en) 2002-04-25
EP1328519A4 (de) 2004-12-15
ATE303998T1 (de) 2005-09-15
AU2002226877B2 (en) 2006-01-12
DE60113286T2 (de) 2006-06-22
US20020072526A1 (en) 2002-06-13
EP1328519A2 (de) 2003-07-23
AU2687702A (en) 2002-04-29
US20040002501A1 (en) 2004-01-01
JP2004511541A (ja) 2004-04-15
EP1328519B1 (de) 2005-09-07
CA2424689A1 (en) 2002-04-25
WO2002032861A3 (en) 2002-08-15
US6960590B2 (en) 2005-11-01
US6656942B2 (en) 2003-12-02
ES2247187T3 (es) 2006-03-01

Similar Documents

Publication Publication Date Title
DE60113286D1 (de) Oral aktive salze mit tyrosinkinaseaktivität
NO20021166D0 (no) Tyrosinkinase-inhibitorer
DE60129672D1 (de) Tyrosinkinase inhibitoren
ATE381332T1 (de) Tyrosinkinase-hemmer
DE60208792D1 (de) Tyrosin-kinase inhibitoren
ATE290865T1 (de) Tyrosin kinase inhibitoren
WO2003088900A3 (en) Solid forms of salts with tyrosine kinase activity
YU28602A (sh) Inhibitori tirozin kinaze
WO2002045652A3 (en) Tyrosine kinase inhibitors
WO2003037252A3 (en) Tyrosine kinase inhibitors
WO2004052315A3 (en) Tyrosine kinase inhibitors
WO2004052286A3 (en) Tyrosine kinase inhibitors
WO2004041164A3 (en) Kinase inhibitors
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
DE602005023732D1 (de) Pyrrolotriazinverbindungen
WO2003020699A3 (en) Tyrosine kinase inhibitors
WO2003015717A3 (en) Tyrosine kinase inhibitors
ECSP003729A (es) Inhibidores de la tirosina quinasa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8339 Ceased/non-payment of the annual fee